Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.
Yu Pengfei(Zhejiang Cancer Hospital), Xiangdong Cheng(Hangzhou Cancer Hospital), Yian Du(Chinese Academy of Sciences), Zhichao Zheng(Liaoning Cancer Hospital & Institute), Litao Yang(Hospital for Sick Children), Zhiyuan Xu(Zhejiang Cancer Hospital), Zhilong Yan(Ningbo University), Yong Li(Nanchang University), Ping Chen(Ningxia Medical University), Xiaojing Zhang, Hongtao Xu(Lishui Central Hospital), Yingjie Wu(Dalian Medical University), Zhiheng Chen(Jiaxing University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Nong Xu(First Affiliated Hospital Zhejiang University), Yunhai Wei(Huzhou Central Hospital)
Cited by 0
Related Papers
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China
|Hepatology|2020|448